Abstract
Purpose To investigate psychological reactions and quality of life among patients with posterior uveal melanoma.
Methods Consecutive patients with uveal malignant melanoma (99/106), referred to st Erik's Eye Hospital 1995–1996, treated with rutheniuim plaque radiotherapy (n = 50) or enucleation (n = 49), were included in this non-randomised prospective comparative study. Questionnaires were completed before treatment (Hospital Anxiety and Depression Scale, HAD scale) and 2 and 12 months after diagnosis including the HAD scale, the Impact of Event Scale and the EORTC QLQ-C30. A disease-specific questionnaire was included 12 months after diagnosis. Between-group differences were analysed by chi-square, Student's t-test and ANOVA.
Results A majority of the patients reported reduced ‘Quality of Life’ (72–85%), ‘Emotional functioning’ (60–74%) and ‘Cognitive functioning’ (51–61%). ‘Fatigue’ was the most frequently reported symptom (61–72%) followed by ‘Insomnia’ (43–58%). Anxiety and depressive symptoms were relatively frequent up to 1 year after treatment, but the levels of anxiety decreased during the first year after treatment. Disease and treatment-related problems were reported in both treatment groups 1 year after diagnosis. Enucleated patients had more problems with appearance and judging distances, whereas those treated with radiotherapy reported vision impairment to a higher extent.
Conclusion Enucleated patients reported high levels of emotional distress, problems with appearance and judging distances during the first year after treatment. Patients treated with radiotherapy reported similar levels of quality of life and emotional problems, but more problems with visual impairment. These differences in impact on disease-related functioning should be taken into account when treatment options are discussed.
Similar content being viewed by others
Article PDF
References
Seregard S . Posterior uveal melanoma: the Swedish perspective. Acta Ophthalmol Scand 1996;74:315–29.
Seregard S, af Trampe E, Lax I, et al. Results following episcleral plaque radiotherapy for posterior uveal melanoma. Acta Ophthalmol Scand 1997;75:11–6.
Seregard S, Lundell G, Lax I, et al. Tumour cell proliferation after failed ruthenium plaque therapy for posterior uveal melanoma. Acta Ophthalmol Scand 1997;75:148–54.
Seregard S, Kock E . Prognostic indicators following enucleation for posterior uveal melanoma. Acta Ophthalmol Scand 1995;73:340–4.
Edwards MG, Schachat AP . Impact of enucleation for choroidal melanoma on the performance of vision-dependent activities. Arch Ophthalmol 1991;109:519–21.
Augsberger JJ, Goel SD . Visual function following enucleation or episcleral plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol 1994;112:786–9.
Olschewski M, Schulgen G, Schumacher M, Altman DG . Quality of life assessment in clinical cancer research. Br J Cancer 1994;70:1–5.
Bunston T, Mackie A, Jones D, Mings D . Identifying the nonmedical concerns of patients with ocular melanoma. J Ophthalmic Nurs Technol 1994;13:227–37.
Albert DN . The ocular melanoma story. LII Edward Jackson Memorial Lecture: part II. Am J Ophthalmol 1997;123:729–41.
Hart PM, Chakravarthy U, Stevenson MR . Questionnaire-based survey on the importance of quality of life measures in ophthalmic practice. Eye 1998;12:124–6.
Cruickshanks KJ, Fryback DG, Nondal DM, et al. Treatment choice and quality of life in patients with choroidal melanoma. Arch Ophthalmol 1999;117:461–7.
Damato B . Disease and ‘dis-ease’ in patients with uveal melanoma [editorial]. Br J Ophthalmol 2000;84:343–5.
Zigmond AS, Snaith RP . The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361–70.
Herrman C . International experiences with the Hospital Anxiety and Depression Scale: a review of validation data and clinical results. J Psychosom Res 1997;42:17–41.
Sullivan M, Karlsson J, Sjostrom L, et al. Swedish obese subject (SOS): an intervention study of obesity. Baseline evaluation of health and psychosocial functioning in the first 1743 subjects examined. Int JObes 1993;17:503–12.
Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76.
Horowitz M, Wilner N, Alvarez W . Impact of Event Scale: a measure of subjective stress. Psychosom Med 1979;41:209–18.
Zielberg NJ, Weiss DS, Horowitz MJ . Impact of Event Scale: a cross-validation study and some empirical evidence supporting a conceptual model of stress response syndromes. J Consult Clin Psychol 1982;50:407–14.
American Psychiatric Association. Diagnostic and statistical manual of retinal disorders. 3rd edn. Washington, DC: APA, 1980.
Horowitz M . Stress response syndromes and their treatment. In: Goldberger L, Breznitz S, editor. Handbook of stress: theoretical and clinical aspects. New York: The Free Press, 1982:711–32.
Foss AJE, Lamping DL, Schroter S, Hungerford J . Development and-validation of a patient based measure of outcome in ocular melanoma. Br J Ophthalmol 2000;84:347–51.
EORTC Quality of Life Study Group. EORTC QLQ C-30 Scoring Manual. Brussels: EORTC Data Center, 1995.
Brandberg Y, Bolund C, Sigurdardottir V, et al. Anxiety and depression at different stages of malignant melanoma. Psycho-Oncology 1992;1:72–8.
Brandberg Y, Mânsson-Brahme E, Ringborg U, Sjôdén PO . Psychological reactions in patients with malignant melanoma. Eur J Cancer 1995;31:157–62.
Lisspers J, Nygren A, Sôderman E . Hospital Anxiety and Depression Scale (HAD): some psychometric data for a Swedish sample. Acta Psychiatr Scand 1997;96:281–6.
Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S . Health related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire: the QLQ-C30 (+3). J Clin Oncol 1998;16:1188–96.
Wisloff F, Hjort M, Kaasa S, Westin J . Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + α interferon. Br J Haematol 1996;94:324–32.
Kaasa S, Malt U, Hagen S, et al. Psychological distress in cancer patients with advanced disease. Radiother Oncol 1993;27:126–34.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brandberg, Y., Kock, E., Oskar, K. et al. Psychological reactions and quality of life in patients with posterior uveal melanoma treated with ruthenium plaque therapy or enucleation: A one year follow-up study. Eye 14, 839–846 (2000). https://doi.org/10.1038/eye.2000.233
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1038/eye.2000.233
Keywords
This article is cited by
-
Predictors of emotional distress in uveal melanoma survivors: a systematic review
Eye (2023)
-
Fear of prognosis? How anxiety, coping, and expected burden impact the decision to have cytogenetic assessment in uveal melanoma patients
Supportive Care in Cancer (2022)
-
Quality of life and treatment-related burden during ocular proton therapy: a prospective trial of 131 patients with uveal melanoma
Radiation Oncology (2021)
-
A prospective study of cancer-related benefit finding in uveal melanoma patients
Journal of Behavioral Medicine (2021)
-
Psychosocial impact of prognostic genetic testing in uveal melanoma patients: a controlled prospective clinical observational study
BMC Psychology (2020)